Melanoma genomics reveals signatures of sensitivity to bio- and targeted therapies.
Most of the melanoma markers used today are melanocytic markers or pigmentation pathway-associated genes driven by the microphthalmia transcription factor, MITF, and include among others, tyrosinase, dopachrome tautomerase, DCT, melan-A and S100B. Genomic studies repeatedly revealed several novel melanoma marker genes including those of the transcription factor NOTCH2, WNT5A, proliferation-associated genes TOPO2A and CDC2, membrane receptors FGFR and EphA3, adhesion molecules N-cadherin, beta3 integrin and syndecan-4, and the cell surface antigens CD59/protectin and MIA. Other genomic analyses tried to define the gene signature of the metastatic disease but failed to find a consistent one except the gold standard genes of beta3 integrin, syndecan-4 and WNT5a. Studies on the gene signatures of chemoresistance and cytokine sensitivity of melanoma clearly defined apoptosis-resistance as one of the key elements of the above biological properties, but the data are controversial, mostly because of the use of inappropriate model systems and the lack of confirmation on clinical samples. Accordingly, application of genomic technologies must be more "translational" to provide breakthrough in melanoma diagnosis and therapy.
Tímár
J
J
Department of Tumor Progression, National Institute of Oncology, Ráth György u. 7-9, H-1122 Budapest, Hungary. jtimar@oncol.hu
Mészáros
L
L
Ladányi
A
A
Puskás
L G
LG
Rásó
E
E
D014408:Biomarkers, Tumor / Q000235:genetics; D023281:Genomics; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000235:genetics* / Q000276:immunology / Q000628:therapy*; D012878:Skin Neoplasms / Q000235:genetics* / Q000276:immunology / Q000628:therapy*
D014408:Biomarkers, Tumor